Outcome and prognostic factors for pediatric patients receiving an haploidentical transplantation using Hospital Infanti Universitario P680 no Jesús CD3/CD19 depleted grafts

Miguel Angel Díaz; Antonio Perez; José Luis Vicario; Manuel Ramirez; Julian Sevilla and Marta Gonzalez-Vicent. Hematopoietic Stem Cell Transplantation Unit. H. Niño Jesús (Madrid, Spain)

Abstract

Since 2005 to December 2014, 75 children with hematological matignancies underwent a total of 70 haploHSCT using CD3+CD19+ deplation for PBPC manipulation. Nincteen patients were in st CR, 30 in 2nd CR and 28 were in >2nd CR or persistent disease. The conditioning regimen consisted of 1.v. fludrablin, busulfar and thiotepa. Allografts contained a modian of 7.29 x10⁶ CD3 cells/kg, and 1.0 x. 10⁶ CD3 cells/kg, Median times to neutrophil and platelut recovery were 13 and 10 dsys, respectively. The probability of severe a GvHD and GcHD (and GcHD) and 23±5⁶ w and 46±7⁶ respectively. NRM was 10±4⁶ by day +100 and 23±5⁶ w and detar transplant. Causes of dead were relapse in 13 cases, viral infections in 8, microangiopathy in 3, graft and others in 2. The probability of relapse was 32±6⁶. With a median follow-up of 22 months, the probability of DFS was 52±6⁶. On a multivariate analysis the factors that positive impact on DFS were age below '12 years (HR: 2.18, p=0.04), GVHD (HR: 2.56, p=0.045), early disease status (HR: 2.30, p=0.04) and donor KR B Haplotype (HR: 2.59, p=0.01). Our results suggest that high-risk hematological malignancies who need an allogeneic transplantation. Graft manipulation results on low incidence of severe aGVHD. NRM was higher in patients over 12 years. DFS was better for patients in arty phase of disease, using KIR B haplotype donors and with GO+HD mainy due to lower relapse incidence. Severe viral infections is a relevant problem in the early phase after transplantation. donors and w Severe viral inf transplantation

Background

Nowadays, haploidentical hematopoletic stem cell transplantation using T-cell depleted grafts is an option for pediatric patients with hematological malignancies in need an allogeneic transplantation and lacking an ILA-identical donor. CD3/CD19 depletion as graft manipulation method retains large numbers of important immune cells in the graft as well as "unaltered" CD34+ However, few papers have been reported addressing pronostic factors and outcomes.

Transplants (n=75) Patients (n=70)

Age	9 years (6 months- 19 years) 48 male/ 27 female 30 (6-76)	
Gender		
Weight (Kg)		
Lansky (%)	90 (60-100)	
<u>Diagnosis</u> ALL AML/MDS/JMML	38 37	
Disease status: - 1st CR - 2nd CR - >2nd CR - Not in remission	19 30 12 14	
<u>Transplant number</u> 1st 2nd 3rd	51 22 2	
Median follow-up	22 months (3-108)	

Donors

Age (years)	40 (2-54)
Gender	25 male/ 50 female
Mother/Father/Brother	48/19/8
KIR match	35 y / 30 n
KIR haplotype	19 A/ 56 B
Cell composition	2 P
- CD34+ x 106/kg	7.02 (1.19-41.6)
- CD3+ x 10 ³ /kg	10.5 (1.0-11.8)
- CD56+ x 10 ⁶ /kg	24.6 (2.57-141.3)

Methods

Since 2005 to 2014, pediatric patients diagnosed of high-risk hematological malignancies with transplantation criteria and good clinical condition were included in the study protocol. Patients do not have time to be waiting for searching a high resolution MUD or lack a MRD or MUD.

Primary "endpoint" is disease-free survival and factors affecting DFS. Secondary "endpoints" are engrafiment kinetics, immune reconstitution, NRM and relapse incidence. Univariate and multivariate analyses were performed using log-rank test and Cox regression model. Pediatric patients were conditioned with fludarabine, busulphan and thiotepa regimen.

4 Fludarabine 4 * * J.

Busulfan		~	•				
3.2- 4.8 mg/Kg/	day						
Thiotepa				0	0		
5 mg/Kg/day							
	-6	-5	-4	-3	-2	-1	0

Donors were mobilized with filgrastim (10 µg/kg/day

CliniMacs (Miltenyi Biotec) device. The final cellular product was infused fresh on day 0.

Results

Hematopoietic engraftment

Days to neutrophil engraftment	13 (7-21)	
Days to platelets $\geq 20 \times 10^3$	10 (5-70)	
Days to platelets $\ge 50 \times 10^3$	13 (5-150)	
Days to platelets ≥ 100 x 10 ³	15 (5-270)	


Supportive care


Red blood cells days	2 (0-21)
Platelets days	3 (0-40)
Parenteral nutrition days	0 (0-40)
Fever days	1 (0-15)
Antibiotic days	12 (0-40)
Hospitalization days	15 (10-41)

Complications

Acute GVHD (any grade)	36 ± 6%
Chronic GVHD	46 ± 7%
Graft failure	13 ± 4%
NRM (day +100)	$10 \pm 4\%$
Overall NRM	$23 \pm 5\%$

Immune reconstitution





DFS multivariate analysis

2000

3000


4000

1000

Variable	HR (CI 95%)	р	
Chronic GVHD Yes	2.56 (0.99-6.63)	0.045	
Age Child	2.18 (1.04-4.55)	0.04	
Disease status Early 8.30 (1.09-62.7)		0.04	
KIR haplotype B	2.59 (1.19-5.63)	0.01	

Conclusions

- HAPLOIDENTICAL TRANSPLANTATION USING TCD IS ASSOCIATED WITH ENCOURAGING RESULTS ESPECIALLY IN PATIENTS IN EARLY PHASE OF DISEASE. 1)
- THASE OF DISEASE. KIR B HAPLOTYPE DONORS CONFER A RAPID NK CELLS EXPANSION EARLY AFTER TRANSPLANTATION, RESULTING ON LOWER PROBABILITY OF RELAPSE AND SUGGESTING A GVL EFFECT APART FROM GVHD 2)
- HOWEVER, THE INCIDENCE OF SEVERE VIRAL INFECTIONS IS THE MAIN PROBLEM TO OVERCOME FOR REDUCING NRM (MAINLY IN ADOLESCENTS) AND IMPROVING RESULTS 3)



References

1. KIR B haplotype donors confer a reduced risk for relapse after haploidentical transplantation in children with ALL Lena Oevermann et al. Blood. 2014;124: 2744-2747. Lena Oevermann et al. Blood. 2014;124: 2744-2747. 2. Transplantation of CD3/CD19 depleted allografts from haploidentical family donors in paediatric leukaemia Peter Lang et al. British Journal of Haematology, 2014; 165: 688–698. 3. Early evaluation of immune reconstitution following allogeneic CD3/CD19-depleted grafts from alternative donors in childhood acute leukami. Perez-Martinez A et al. Bone Marrow Transplantation 2012; 47: 1419 – 1427. 2012; 47: 1419 – 1427. 4. Graft Manipulation and Reduced-intensity Conditioning for Allogeneic Hematopoietic Stem Cell Transplantation From Mismatched Unrolated and Mismatched/Hapioidentical Related Donors in Pediatric Leukemia Patients. Gonzalez-Vicent M, et al. Journal of Pediatric Hematology/Oncology 2010; 32: 85-90.